HARMONY BIOSCIENCES HOLDINGS (HRMY) Stock Price & Overview
NASDAQ:HRMY • US4131971040
Current stock price
The current stock price of HRMY is 27.85 USD. Today HRMY is down by -1.83%. In the past month the price decreased by -21.06%. In the past year, price decreased by -21.06%.
HRMY Key Statistics
- Market Cap
- 1.611B
- P/E
- 10.28
- Fwd P/E
- 7.69
- EPS (TTM)
- 2.71
- Dividend Yield
- N/A
HRMY Stock Performance
HRMY Stock Chart
HRMY Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to HRMY. When comparing the yearly performance of all stocks, HRMY is a bad performer in the overall market: 85.61% of all stocks are doing better.
HRMY Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to HRMY. HRMY scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
HRMY Earnings
On February 24, 2026 HRMY reported an EPS of 0.38 and a revenue of 243.78M. The company missed EPS expectations (-58.44% surprise) and missed revenue expectations (-0.58% surprise).
HRMY Forecast & Estimates
17 analysts have analysed HRMY and the average price target is 46.55 USD. This implies a price increase of 67.14% is expected in the next year compared to the current price of 27.85.
For the next year, analysts expect an EPS growth of 33.68% and a revenue growth 17.98% for HRMY
HRMY Groups
Sector & Classification
HRMY Financial Highlights
Over the last trailing twelve months HRMY reported a non-GAAP Earnings per Share(EPS) of 2.71. The EPS increased by 7.97% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 18.27% | ||
| ROA | 12.48% | ||
| ROE | 18.24% | ||
| Debt/Equity | 0.17 |
HRMY Ownership
HRMY Latest News, Press Relases and Analysis
HRMY Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.26 | 877.655B | ||
| JNJ | JOHNSON & JOHNSON | 20.37 | 573.821B | ||
| MRK | MERCK & CO. INC. | 22.12 | 286.476B | ||
| PFE | PFIZER INC | 9.15 | 156.088B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.37 | 121.598B | ||
| ZTS | ZOETIS INC | 16.58 | 51.365B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.86 | 26.599B | ||
| VTRS | VIATRIS INC | 5.48 | 15.889B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.6 | 12.519B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.244B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.055B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.935B | ||
| LGND | LIGAND PHARMACEUTICALS | 24.67 | 4.207B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About HRMY
Company Profile
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania and currently employs 293 full-time employees. The company went IPO on 2020-08-19. The company is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. WAKIX was developed for the treatment of excessive daytime sleepiness (EDS) in pediatric patients, six years and older, with narcolepsy. HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist. ZYN002 is an investigational drug product in development for the potential treatment of behavioral symptoms associated with Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q). The company also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.
Company Info
IPO: 2020-08-19
HARMONY BIOSCIENCES HOLDINGS
630 W Germantown Pike, Suite 215
Plymouth Meeting PENNSYLVANIA 19462 US
CEO: John C. Jacobs
Employees: 293
Phone: 13026587581
HARMONY BIOSCIENCES HOLDINGS / HRMY FAQ
Can you describe the business of HARMONY BIOSCIENCES HOLDINGS?
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania and currently employs 293 full-time employees. The company went IPO on 2020-08-19. The company is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. WAKIX was developed for the treatment of excessive daytime sleepiness (EDS) in pediatric patients, six years and older, with narcolepsy. HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist. ZYN002 is an investigational drug product in development for the potential treatment of behavioral symptoms associated with Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q). The company also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.
What is the stock price of HARMONY BIOSCIENCES HOLDINGS today?
The current stock price of HRMY is 27.85 USD. The price decreased by -1.83% in the last trading session.
What is the dividend status of HARMONY BIOSCIENCES HOLDINGS?
HRMY does not pay a dividend.
What is the ChartMill rating of HARMONY BIOSCIENCES HOLDINGS stock?
HRMY has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the analyst forecast for HRMY stock?
17 analysts have analysed HRMY and the average price target is 46.55 USD. This implies a price increase of 67.14% is expected in the next year compared to the current price of 27.85.
Can you provide the market cap for HARMONY BIOSCIENCES HOLDINGS?
HARMONY BIOSCIENCES HOLDINGS (HRMY) has a market capitalization of 1.61B USD. This makes HRMY a Small Cap stock.